For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research And Development | 1,370 | 2,377* | 2,157 | 1,018 |
| General And Administrative | 1,379 | 891* | 1,135 | 1,266 |
| Total operating expenses | 2,749 | 3,267 | 3,292 | 2,284 |
| Operating loss | - | -3,267* | -3,292 | -2,284 |
| Financial expenses | -16 | -2* | -30 | 216 |
| Loss before income tax | -2,733 | -3,265* | -3,262 | -2,500 |
| Income tax | - | -1* | 0 | 3 |
| Net loss | -2,733 | -3,264 | -3,262 | -2,503 |
| Basic EPS | 0.85 | -2.455 | 2.88 | 4.32 |
| Diluted EPS | 0.85 | -2.455 | 2.88 | 4.32 |
| Basic Average Shares | 3,230,378 | 1,329,515* | 1,132,658 | 579,523 |
| Diluted Average Shares | 3,230,378 | 1,329,515* | 1,132,658 | 579,523 |
Silexion Therapeutics Corp (SLXNW)
Silexion Therapeutics Corp (SLXNW)